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A B S T R A C T
Background
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable respiratory disease. COPD exacerbations
are associated with worse quality of life, increased hospitalisations, and increased mortality. Currently available pharmacological
interventions have variable impact on exacerbation frequency. The anti-inflammatory eIects of statins may lead to decreased pulmonary
and systemic inflammation, resulting in fewer exacerbations of COPD. Several observational studies have shown potential benefits of
statins for patients with COPD.
Objectives
This review aims to evaluate available evidence on benefits and harms associated with statin therapy compared with placebo as adjunct
therapy for patients with COPD. Primary objectives include the following.
• To determine whether statins reduce mortality rates in COPD.
• To determine whether statins reduce exacerbation frequency, improve quality of life, or improve lung function in COPD.
• To determine whether statins are associated with adverse eIects.
Search methods
We identified trials from the Cochrane Airways Trials Register, which contains studies identified through multiple electronic searches and
handsearches of other sources. We also searched trial registries and reference lists of primary studies. We conducted the most recent search
on 20 May 2019.
Selection criteria
Parallel, randomised controlled trials recruiting adults with COPD.
Data collection and analysis
We used standard methods as expected by Cochrane. Prespecified primary outcomes were number of exacerbations, all-cause mortality,
and COPD-specific mortality.
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Main results
Eight studies including 1323 participants with COPD were included in the review. Participants had a mean age of 61.4 to 72 years, and most
were male (median 73.4%). Mean baseline forced expiratory volume in one second (FEV1) ranged from 41% to 90% predicted. All studies
compared moderate- or high-intensity statin therapy versus placebo. The duration of treatment ranged from 12 weeks to 36 months.
We found no statistically significant diIerence between statins and placebo in our primary outcome of number of exacerbations per person-
year (mean diIerence (MD) -0.03, 95% confidence interval (CI) -0.25 to 0.19, 1 trial, 877 participants), including number of exacerbations
requiring hospitalisation per person-year (MD 0.00, 95% CI -0.10 to 0.10, 1 trial, 877 exacerbations). This evidence was of moderate quality
aLer downgrading for unclear risk of bias. Our primary outcomes of all-cause mortality (odds ratio (OR) 1.03, 95% CI 0.61 to 1.74, 2 trials, 952
participants) and COPD-specific mortality (OR 1.25, 95% CI 0.38 to 4.13, 1 trial, 877 participants) showed no significant diIerence between
statins and placebo, with wide confidence intervals suggesting uncertainty about the precision of the results. This evidence was of low
quality aLer downgrading for unclear risk of bias and imprecision.
Results of the secondary outcomes analysis showed no clear diIerences between statins and placebo for FEV1 (% predicted) (MD 1.18, 95%
CI -2.6 to 4.97, 6 trials, 325 participants) but did show a statistically significant improvement in FEV1/forced vital capacity (FVC) (MD 2.66,
95% CI 0.12 to 5.2; P = 0.04; 6 trials, 325 participants). A sensitivity analysis excluding two trials at high risk of bias showed no statistically
significant diIerence in FEV1/FVC (MD 2.05, 95% CI -0.87 to -4.97; P = 0.17; 4 trials, 255 participants). We also found no significant diIerences
between the two groups in functional capacity measured by six-minute walk distance in metres (MD 1.79, 95% CI -52.51 to 56.09, 3 trials,
71 participants), with wide confidence intervals suggesting uncertainty about the precision of the results. Results show no clear diIerence
in quality of life, which was reported in three trials, and a slight reduction in C-reactive protein (CRP) in the intervention group, which
was statistically significant (MD -1.03, 95% CI -1.95 to -0.11; I2 = 0%, P = 0.03; 3 trials, 142 participants). We noted a significant reduction in
interleukin (IL)-6 in the intervention group (MD -2.11, 95% CI -2.65 to -1.56; I2 = 0%, P ≤ 0.00001; 2 trials, 125 participants). All trials mentioned
adverse events and indicated that statins were generally well tolerated. One study reported adverse events in detail and indicated that
rates of all non-fatal adverse events (the number of serious adverse events per person-year) were similar in both groups (0.63 ± 1.56 events
(intervention group) and 0.62 ± 1.48 events (control group); P > 0.20) for all comparisons, except for non-fatal serious adverse events
involving the gastrointestinal tract, which were more frequent in the intervention group (in 30 patients (0.05 events per person-year) vs 17
patients (0.02 events per person-year); P = 0.02). Another trial lists the total numbers and percentages of adverse events in the intervention
group (12 (26%)) and in the control group (21 (43%)) and of serious adverse events in the intervention group (4 (9%)) and in the control
group (3 (6%)).The other trials stated that researchers found no significant adverse eIects of statins but did not report adverse events in
detail.
Authors' conclusions
A small number of trials providing low- or moderate-quality evidence were suitable for inclusion in this review. They showed that use
of statins resulted in a reduction in CRP and IL-6, but that this did not translate into clear clinical benefit for people with COPD. Further
randomised controlled trials are needed to explore this topic.
P L A I N   L A N G U A G E   S U M M A R Y
Statins for chronic obstructive pulmonary disease (COPD)
Review question
We reviewed the evidence on the eIects of statins on adults with COPD. We found eight relevant studies.
Background
Chronic obstructive pulmonary disease (COPD) is the name for a group of progressive lung conditions that cause breathing diIiculties.
This group includes emphysema and chronic bronchitis. Statins are medicines that can help lower the level of cholesterol in the blood.
It has been suggested that through their anti-inflammatory properties statins might help reduce the number of exacerbations in people
with COPD.
Study characteristics
We included eight studies involving 1323 participants comparing the benefits and harms of statins and placebo (an identical looking
treatment with no therapeutic benefit) in people with COPD.
Key results
We found that statins reduced the level of inflammation in people with COPD but that this did not result in any clear improvement in
exacerbations, mortality, functional capacity, quality of life, or lung function. Statins were generally well tolerated and were associated
with few adverse eIects.
Quality of the evidence
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This evidence was of low or moderate quality, and most came from trials of short duration.
This review is current to May 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Statins compared to placebo as adjunct therapy for chronic obstructive pulmonary disease (COPD)
Statins compared to placebo as adjunct therapy for chronic obstructive pulmonary disease (COPD)
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Quality of life Two studies used the St. George's Respiratory Questionnaire (SGRQ). One study reported me-
dian change from baseline score and found no significant improvement in any of the domains
of the SGRQ (total SGRQ median change from baseline -0.18 (10th, 90th percentiles -11.01, 9.7)
in the intervention group and 0.02 (10th, 90th percentiles -12.47, 10.73) in the control group; P
= 0.3783) or the Short Form Health Survey (SF-36) with statin treatment. One study found that
the median SGRQ score decreased significantly from 54.5 to 42 in the intervention group com-
pared with no change in the control group (68 to 70 points; non-significant). A third trial found
that mean change in Clinical COPD Questionnaire (CCQ) total score (P = 0.96) and symptom
score (P = 0.12) was not significant at 12 weeks but did not provide further data
(3 RCTs) Not applicable  
Adverse events One study found that rates of all non-fatal adverse events were similar in both groups for all
comparisons, except for non-fatal serious adverse events involving the gastrointestinal tract,
which were more frequent in the intervention groups. One study reported the total numbers
and percentages of adverse events (12 (26%) in the intervention group and 21 (43%) in the con-
trol group) and serious adverse events (4 (9%) in the intervention group and 3 (6%) in the con-
trol group). One study reported no adverse events, although 1 person was not included in the
final analysis owing to serious adverse events and there was 1 case of CAP. One study report-
ed that rosuvastatin was well tolerated, but common adverse drug reactions were gastric intol-
erance, myalgia, and elevated AST. Pedal oedema was seen in 2 patients in the placebo group
who were on calcium channel blockers. Four studies reported no side effects
(8 RCTs) Not applicable  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
AST: aspartate transaminase; CAP: community-acquired pneumonia; CI: confidence interval; MD: mean difference; OR: odds ratio; RCT: randomised controlled trial; RR: risk
ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one point as unclear risk of selection and detection bias.
bDowngraded by one point as unclear risk of selection and detection bias, unclear risk of reporting bias.
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B A C K G R O U N D
Description of the condition
"Chronic obstructive pulmonary disease (COPD) is a common,
preventable and treatable disease, which is characterized by
persistent respiratory symptoms and airflow limitation that is
due to airway and/or alveolar abnormalities usually caused by
significant exposure to noxious particles or gases. Exacerbations
negatively impact health status, rates of hospitalisation and disease
progression" (GOLD 2019). It is estimated that 65 million people
worldwide have moderate to severe COPD (WHO 2015). Although
mortality from cancer, heart disease, and stroke has decreased,
mortality from COPD has increased by 102% (Jemal 2005). COPD
is currently the third leading cause of death worldwide (WHO
2018). A systematic review of population studies of COPD estimated
prevalence of 9% to 10% in adults over 40 years of age (Halbert
2006). A Burden of Obstructive Lung Disease Initiative (BOLD) (Buist
2005) study estimated the population prevalence of GOLD (Global
Initiative for Chronic Obstructive Lung Disease) stage 2 or higher
COPD at 8.5% to 22.2% across 12 international cities and observed
significant variation in prevalence across sites (Buist 2007). The
Latin American Project for the Investigation of Obstructive Lung
Disease (PLATINO) study reported a crude prevalence rate of GOLD
stage 1 or higher COPD of 9.7% to 19.7% across five South American
cities (Menezes 2005). In a prevalence study in Austria, 26.1% of the
population over 40 years of age had GOLD stage 1 or higher COPD
(Schirnhofer 2007). In the United States, the estimated economic
cost of COPD and asthma combined is $68 billion (NHLBI 2012).
Exacerbations of COPD are responsible for the largest portion
of the COPD burden on the healthcare system (Strassels 2001).
GOLD defines a COPD exacerbation as "an acute worsening of
respiratory symptoms that result in additional therapy" (GOLD
2019). Acute exacerbations are associated with worse quality of
life (Barnes 2013), increased hospitalisations (Mullerova 2014),
increased mortality (Seemungal 2008), inflammation (Lopez-
Campos 2015; Seemungal 2001), and lung hyperinflation (Parker
2005; Van GeIen 2018). Several interventions are available to
prevent exacerbations, including smoking cessation, pulmonary
rehabilitation, and disease management programmes; patient
education; non-invasive ventilation; pneumococcal and influenza
vaccinations; and use of long-acting bronchodilators, inhaled
corticosteroids, phosphodiesterase 4 inhibitors, antioxidants,
mucolytic agents, and antibiotics (Qureshi 2014). The eIects
of these interventions on exacerbation frequency are limited,
with pharmacological interventions leading to a 14% to 35%
reduction (Han 2011). Smoking cessation has been shown to
modify the accelerated rate of decline in lung function that is
the hallmark of COPD (Godtfredsen 2008). A recent trial showed
that triple therapy (combination of an inhaled glucocorticoid, a
long-acting muscarinic antagonist (LAMA), and a long-acting beta-
agonist (LABA)) resulted in improved lung function compared to
dual therapy with either inhaled glucorticoid-LABA or LAMA-LABA
(Lipson 2018), but it remains to be conclusively proven whether any
of the existing pharmacological interventions for COPD modify the
long-term decline in lung function (GOLD 2019). The importance
of finding treatments that can have this kind of impact cannot be
overstated.
COPD is increasingly considered a multi-system disease involving
pulmonary and systemic inflammation (Young 2013). The lung
inflammatory response comprises increased concentrations of
pro-inflammatory cytokines, as well as innate and adaptive
immune cells (Sinden 2010). A systematic review found that
people with COPD had raised levels of several inflammatory
markers, including interleukin-6 (IL-6) and C-reactive protein (CRP),
indicating the presence of persistent systemic inflammation (Gan
2004). Pulmonary and systemic inflammation is thought to be
central to symptoms, exacerbations, and mortality (Young 2009). In
addition, many patients with COPD have multiple comorbidities,
particularly those who are elderly (Clini 2013).
Description of the intervention
Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors and are among the most powerful available
cholesterol-lowering drugs. Currently available statins include
simvastatin, pravastatin, rosuvastatin, atorvastatin, fluvastatin,
pitavastatin, and lovastatin (FDA 2015). They are oral drugs that are
taken daily, usually on a long-term basis.
How the intervention might work
Statins are competitive inhibitors of HMG-CoA reductase - the
enzyme that catalyses the rate-limiting step in cholesterol
biosynthesis (Istvan 2001). Statins have multiple biochemical
eIects in addition to their lipid-lowering properties, including anti-
inflammatory eIects (Antonopoulos 2012). They are inhibitors of
IL-6 and CRP and have extrahepatic eIects, including eIects in
the lung (Yeganeh 2014). The anti-inflammatory eIects of statins
may lead to decreased pulmonary and systemic inflammation,
resulting in fewer exacerbations, reduced decline in lung function,
and improved life expectancy in COPD (Young 2013). Evidence
also suggests that dyslipidaemia and surfactant disturbance may
contribute to inflammation and increased airway resistance in
COPD (Chai 2017; Hohlfeld 1997; Morissette 2015).
Several observational studies have shown potential benefits of
statins as adjunct therapy for patients with COPD. Researchers
report reduced all-cause mortality (Frost 2007; Ishida 2007;
Lahousse 2013; Lawes 2012; Mancini 2006; Raymakers 2017;
Sheng 2012), fewer COPD exacerbations (Balmoun 2008; Bartziokas
2011; Huang 2011; Ingebrigtsen 2015; Wang 2013), and reduced
decline in lung function (AlexeeI 2007). However, observational
studies have limitations because of the uncontrolled nature of
the populations studied. Systematic reviews and meta-analyses
including observational studies on the eIects of statins on
mortality in COPD showed moderate to considerable heterogeneity
(Cao 2015; Li 2017; Lu 2019), along with evidence of publication bias
(Horita 2014).
Numerous controlled trials including thousands of participants
have studied statins from a safety perspective and have reported
that they are generally well tolerated (Baigent 2005; Bays 2005;
Finegold 2014; Kashani 2006; Silva 2006). Clinicians can monitor
well-recognised adverse eIects on muscle and on liver function
(Bays 2014; Rosenson 2014). Statins are also associated with
increased risk of type 2 diabetes (Sattar 2014).
Why it is important to do this review
Statins are widely available; beneficial eIects, when they occur,
lead to reduction in exacerbations, hospital admissions, and
mortality among patients with COPD, and have wide-reaching
implications for international healthcare systems and millions
of people worldwide. Like all drugs, statins have side eIects
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)
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and should not be prescribed unless they are known to benefit
the patient. A meta-analysis of randomised controlled trials is
necessary to fully evaluate evidence from randomised controlled
trials on statins as adjunct therapy in COPD.
O B J E C T I V E S
This review aims to evaluate available evidence on benefits and
harms associated with statin therapy compared with placebo as
adjunct therapy for patients with COPD. Primary objectives include
the following.
• To determine whether statins reduce mortality rates in COPD.
• To determine whether statins reduce exacerbation frequency,
improve quality of life, or improve lung function in COPD.
• To determine whether statins are associated with adverse
eIects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) reported as
full text, published as abstract only, or providing only unpublished
data.
Types of participants
We included adults (≥ 18 years of age) with a diagnosis of COPD as
defined by GOLD criteria (GOLD 2015; Rabe 2007), or by American
Thoracic Society (ATS) or European Respiratory Society (ERS)
criteria (Celli 2004). We included participants with stable and
unstable COPD.
Types of interventions
We included trials comparing any statin at any dose given for 12
weeks or longer versus placebo.
Types of outcome measures
Primary outcomes
• Number of exacerbations (exacerbations will be further defined
as exacerbations requiring short-acting bronchodilators only,
exacerbations requiring short-acting bronchodilators and a
course of antibiotics or steroids, exacerbations requiring





• Validated quality of life measures (e.g. St. George's Respiratory
Questionnaire (Jones 1992), self-reported Chronic Respiratory
Questionnaire (Guyatt 1987))
• Functional capacity (e.g. six-minute walk distance test (Balke
1963), incremental shuttle walking test (Singh 1992), endurance
shuttle walking test (Revill 1999))
• Lung function including spirometric measurements (forced
expiratory volume in one second (FEV1), forced vital capacity
(FVC), FEV1/FVC)
• Measures of airway inflammation such as CRP, IL-6, and tumour
necrosis factor (TNF)-alpha
• Adverse events/Side eIects
Reporting by researchers of one of more of the outcomes listed here
is not an inclusion criterion for this review.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Airways Trials Register on 20 May
2019. The Cochrane Airways Trials Register is maintained by the
Information Specialist for the Group and contains studies identified
from several sources.
• Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL), in the Cochrane Library, via the Cochrane
Register of Studies (CRS).
• Weekly searches of MEDLINE Ovid.
• Weekly searches of Embase Ovid.
• Monthly searches of PsycINFO Ovid.
• Monthly searches of the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) EBSCO.
• Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
• Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference
proceedings, are provided in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review.
We searched the following trials registries on 20 May 2019.
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch).
We did not apply restrictions to searches based on date, type, or
language of publication.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references. We searched relevant manufacturers' and
clinical trials websites for trial information.
We searched for errata or retractions from included studies
published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
on 07 June 2019.
Data collection and analysis
Selection of studies
Two review authors (AW and LP) independently screened titles and
abstracts to identify potential studies for inclusion in the review;
we coded studies identified by the search as 'retrieve' (eligible
or potentially eligible/unclear) or 'do not retrieve'. We retrieved
full-text study reports/publications; two review authors (AW and
LP) independently screened the full text, identified studies for
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)
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inclusion, and identified and recorded reasons for exclusion of
ineligible studies. We encountered no disagreements, so the need
to consult a third review author (MNC) did not arise. We identified
and excluded duplicates and collated multiple reports of the
same study, so that each study rather than each report is the
unit of interest in the review. We recorded the selection process
in suIicient detail to complete a Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (see
Figure 1) and a Characteristics of excluded studies table.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Data extraction and management
Two review authors (AW and LP) used a data collection form that
was piloted on one study in the review to record the following study
characteristics and outcome data from included studies.
• Methods: study design, total duration of study, details of any
'run-in' period, number of study centres and locations, study
setting, withdrawals, and dates of study.
• Participants: number, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
• Interventions: interventions, comparison, concomitant
medications, and excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected and time points reported.
• Notes: funding for trial and notable conflicts of interest of trial
authors.
Two review authors (AW and LP) independently extracted outcome
data from included studies. We noted in the Characteristics of
included studies table if outcome data were not reported in a
usable way. We resolved disagreements by reaching consensus.
One review author (AW) transferred data into the Review Manager
file (RevMan 2014). We double-checked that data were entered
correctly by comparing data presented in the systematic review
versus data provided in the study reports. A second review author
(AK) spot-checked study characteristics for accuracy against the
trial report.
Assessment of risk of bias in included studies
Two review authors (AW and MNC) independently assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions  (Higgins 2011).
We resolved disagreements by discussion and assessed risk of bias
according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the 'Risk of bias' table. We summarised risk
of bias judgements across diIerent studies for each of the domains
listed. We blinded separately for diIerent key outcomes when
necessary (e.g. for unblinded outcome assessment, risk of bias
for all-cause mortality may be very diIerent than for a patient-
reported pain scale). When information on risk of bias relates to
unpublished data or correspondence with a trialist, we noted this
in the 'Risk of bias' table.
When considering treatment eIects, we took into account the risk
of bias for studies that contribute to those outcomes.
Assessment of bias in conducting the systematic review
We conducted the review according to this published protocol and
reported deviations from it in the DiIerences between protocol and
review section of the systematic review.
Measures of treatment e:ect
We analysed dichotomous data by calculating odds ratios (ORs) and
95% confidence intervals (CIs), and continuous data by calculating
mean diIerences (MDs) or standardised mean diIerences (SMDs)
and 95% CIs. We entered data presented as a scale with a consistent
direction of eIect.
Meta-analysis was undertaken only when this was meaningful (i.e.
when treatments, participants, and the underlying clinical question
are similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
Our review did not include trials with multiple intervention arms,
but if future updates of the review should identify this type of trial,
we will include only the relevant arms. When two comparisons (e.g.
drug A vs placebo and drug B vs placebo) were combined in the
same meta-analysis, we halved the control group to avoid double-
counting.
Unit of analysis issues
Our analysis took into account the level at which randomisation
occurred. The study participant was the unit of analysis in all
included studies. We used rate ratios to analyse data to avoid a unit
of analysis error.
Dealing with missing data
We contacted investigators to verify key study characteristics and
obtain missing numerical outcome data when possible. When
this was not possible, and we thought that the missing data
might introduce serious bias, we performed a sensitivity analysis
to explore the impact of including such studies in the overall
assessment of results.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. We interpreted I2 as per the Cochrane Handbook
for Systematic Reviews of Interventions: 0% to 40%: might not be
important; 30% to 60%: may represent moderate heterogeneity;
50% to 90%: may represent substantial heterogeneity; 75% to
100%: may show considerable heterogeneity (Higgins 2011).
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)
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Assessment of reporting biases
As we included fewer than 10 studies in the review, we were
unable to create a funnel plot to explore possible small study and
publication biases.
Data synthesis
We used a random-eIects model and performed a sensitivity
analysis using a fixed-eIect model.
'Summary of findings' table
We created a 'Summary of findings' table by using the following
outcomes: number of exacerbations, all-cause mortality, COPD-
specific mortality, quality of life, and adverse eIects. We used
the eight GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) considerations (study limitations,
consistency of eIect, imprecision, indirectness, publication bias,
magnitude of eIect, possible confounders, and dose-response
gradient) to assess the quality of a body of evidence as it relates
to studies contributing data to the meta-analyses for prespecified
outcomes. We applied methods and recommendations as
described in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), using
GRADEpro soLware. We justified all decisions to downgrade the
quality of studies by using footnotes, and we made comments to
aid readers' understanding of the review, when necessary.
Subgroup analysis and investigation of heterogeneity
Given the small number of trials included in this review, it was not
possible to carry out subgroup analysis. We had planned to carry
out the following subgroup analyses.
• Baseline severity of COPD (we will categorise baseline severity
in three ways: (1) through GOLD spirometric assessment: GOLD
1: mild (FEV1 ≥ 80% predicted), GOLD 2: moderate (50%
≤ FEV1 < 80% predicted), GOLD 3: severe (30% ≤ FEV1 <
50% predicted), GOLD 4: very severe (FEV1 < 30% predicted);
(2) by number of exacerbations (those with fewer than two
previous exacerbations and those with two or more previous
exacerbations); and (3) through a combination of spirometric
assessment and number of exacerbations (comparison of those
with FEV1 < 50% predicted and those who have had two or more
previous exacerbations vs the rest of the study population).
• Smoking status (current smokers/former smokers/never
smokers).
• Statin dose (low-, moderate-, or high-intensity dose, as per
American Heart Association (AHA) guidelines) (Stone 2014).
We had planned to use the following outcomes in subgroup
analyses.
• Number of exacerbations.
• Mortality (all-cause and COPD-specific).
We planned to use the formal test for subgroup interactions
provided in Review Manager (RevMan 2014).
Sensitivity analysis
We planned to perform sensitivity analyses to assess whether
results of our primary outcomes were sensitive to blinding,
completeness of follow-up, publication status, and funding.
We also planned to perform a sensitivity analysis that
would exclude studies including participants with underlying
hypercholesterolaemia or cardiovascular disease. Again, given the
small number of studies included in this review, it was not possible
to perform these sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
One hundred fiLy-five references were identified through searches
of online databases, and one additional reference was found by
searching other resources (drug company websites, reference lists
of systematic reviews, clinicaltrials.gov, and who.int). ALer 79
duplicates were removed, 36 of the remaining 76 references were
excluded by screening references and abstracts. Full texts were
consulted for the remaining 40 references, and 18 met inclusion
criteria, representing eight studies. We excluded 24 studies with
reasons (see Figure 1). Of note, two studies were identified that
were suitable for inclusion in the review, but they had to be
excluded due to lack of available data. Full details of the search
history can be found in Appendix 1 and Appendix 2.
Included studies
Eight studies met the inclusion criteria, randomly assigning 1323
participants with a diagnosis of COPD to statin or placebo.
Design and duration
All eight studies were randomised, parallel-group, placebo-
controlled trials. One of the studies blinded participants but not
personnel (Mroz 2015). The remaining seven studies blinded both
participants and personnel. One trial lasted for three years (Criner
2014), three for six months (Lee 2008; Lee 2009; Moosavi 2013),
and four for 12 weeks (Balaguer 2016; Chogtu 2016; Mroz 2015;
Neukamm 2014).
Participant inclusion and exclusion criteria
Full details of the inclusion and exclusion criteria for each trial
can be found in Characteristics of included studies. Criteria varied
between trials. Various definitions of COPD were used - three
trials used GOLD criteria (Balaguer 2016; Criner 2014; Neukamm
2014), four used American Thoracic Society (ATS) criteria (Lee 2008;
Lee 2009; Moosavi 2013; Mroz 2015), and one used both GOLD
and ATS criteria (Chogtu 2016). Three studies included only those
with at least moderate COPD (Balaguer 2016; Criner 2014; Mroz
2015). Criner 2014 and Mroz 2015 also required participants to
have a smoking history of at least ten pack-years. Three studies
included only patients with pulmonary hypertension secondary
to COPD (Chogtu 2016; Lee 2009; Moosavi 2013). Three trials
excluded participants with a history of hypercholesterolaemia or
cardiovascular disease (Balaguer 2016; Criner 2014; Neukamm
2014).
Baseline characteristics of participants
Full baseline characteristics of the participants in each trial can
be found in Characteristics of included studies. Mean age ranged
from 61.4 to 72 years. Most participants were male (range 49% to
100%, median 73.4%). One trial did not give any information on
gender, percentage of current smokers, or percentage predicted
FEV1 (Chogtu 2016). Another trial gave no information on smoking
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history (Moosavi 2013). The remaining six trials all reported the
percentage of current smokers, which ranged from 0% to 81%, with
a median of 41.7%. Three trials reported pack-year history, with
means ranging from 35 to 51.2 pack-years (Criner 2014; Neukamm
2014), and with medians of 30 to 40 years (Chogtu 2016). Seven
trials reported percentage predicted FEV1, with baseline means
ranging from 41.5% to 59.6%.
Characteristics of the intervention
All studies compared moderate- or high-intensity statin therapy
versus placebo (Stone 2014). Two studies used high-intensity statin
therapy: one used atorvastatin 20 mg orally twice daily for six
months (Moosavi 2013), and the other used atorvastatin 40 mg
orally once daily for 12 weeks (Mroz 2015). The remaining six studies
used moderate-intensity statin therapy: two used pravastatin 40
mg orally once daily for six months (Lee 2008; Lee 2009), one
simvastatin 40 mg orally once daily for 12 to 36 months (Criner
2014), one simvastatin 40 mg orally once daily for 12 weeks
(Balaguer 2016), and two rosuvastatin 10 mg orally once daily for 12
weeks (Chogtu 2016; Neukamm 2014). In all studies, the duration of
the intervention was the same as the duration of the trial.
Outcomes and analysis structure
Two trials reported COPD exacerbations (Criner 2014; Neukamm
2014). Criner 2014 reported exacerbations in detail, including total
number of exacerbations, number of exacerbations per person-
year, time to first exacerbation, and severity of exacerbations.
Neukamm 2014 reported frequency of total exacerbations and
frequency of exacerbations requiring hospitalisation. Chogtu 2016
stated "median COPD exacerbations in rosuvastatin group were less
compared to placebo group with a significant diIerence" but did
not provide any other data. The remaining trials did not provide any
information on exacerbations.
Two trials reported all-cause mortality (Criner 2014; Moosavi 2013).
Criner 2014 was the only trial to report the specific causes of death
and was the only trial to study COPD-specific mortality.
Lung function was reported in all eight trials.
Three studies reported quality of life measures. Both Criner 2014
and Mroz 2015 used the St. George's Respiratory Questionnaire
(SGRQ). Chogtu 2016 used the Clinical COPD Questionnaire (CCQ).
Six trials looked at functional capacity. Lee 2008 and Lee
2009 reported this using the Naughton exercise stress test. The
remaining four trials looked at six-minute walking distance (6MWD)
(Balaguer 2016; Moosavi 2013; Mroz 2015; Neukamm 2014).
Five trials reported measures of airway inflammation. Lee 2008
and Neukamm 2014 reported post-treatment CRP and IL-6. Mroz
2015 reported post-treatment CRP. Balaguer 2016 reported post-
treatment IL-6 and IL-8. Moosavi 2013 stated that "no significant
diIerence in the CRP was found between the two groups at baseline
or 6 months" but did not provide any data.
All of the trials mentioned adverse events. Criner 2014 listed
the cause of serious non-fatal adverse events as number of
events per person-year. Neukamm 2014 listed the total numbers
and percentages of adverse events, serious adverse events,
and suspected unexpected serious adverse reactions. Balaguer
2016 stated that "no participants reported adverse eIects from
simvastatin treatment". Chogtu 2016 stated that "rosuvastatin was
well tolerated by patients. Common adverse drug reactions were
gastric intolerance, myalgia, and elevated AST". Lee 2008 and
Lee 2009 stated that "pravastatin was very well-tolerated by all
patients, and none had any significant subjective side eIects".
Moosavi 2013 stated that "atorvastatin was very well-tolerated by
all patients, and none of them had any significant subjective side
eIects". Mroz 2015 stated that "no side eIects of the treatment were
reported during the study period".
Studies at high risk of bias/those with high or uneven
withdrawal rates
No studies were rated as having high risk of bias for either of the
selection bias parameters. Mroz 2015 was rated as having high risk
of bias for detection and performance bias. Balaguer 2016 and Lee
2009 were rated as having high risk for attrition bias. Reporting bias
is reflected in the GRADE ratings of aIected outcomes.
Excluded studies
We report reasons for exclusion of 17 studies in Characteristics
of excluded studies. We excluded two studies as we were unable
to identify published results despite apparent completion of the
studies six and seven years ago. We contacted the study authors
but received no response. Six trials were less than 12 weeks in
duration. Two publications did not report randomised controlled
trials. Five trials were not placebo controlled, and two trials did not
use a standard or validated definition of COPD for its participants.
Three reports were identified as duplicates at the full-text review
stage, and two were additional reports on studies that were already
excluded.
Risk of bias in included studies
Details of our risk of bias judgements can be found in
Characteristics of included studies. An overview of our risk of bias
judgements is outlined in Figure 2.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
None of the included studies were rated as having high risk
of bias for either of the two allocation parameters (random
sequence generation and allocation concealment). Six studies fully
described methods of random sequence generation and allocation
concealment and were rated as having low risk of bias (Chogtu
2016; Lee 2008; Lee 2009; Moosavi 2013; Mroz 2015; Neukamm
2014). Two studies did not provide details of random sequence
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generation or allocation concealment and were therefore rated as
having unclear risk of bias (Balaguer 2016; Criner 2014).
Blinding
One trial was rated as having high risk of performance and
detection bias, as it explicitly stated that it was a single-blind study
and that personnel were not blinded at any stage (Mroz 2015). The
remaining seven trials were rated as having low risk of performance
bias, as all were double-blind studies in which participants and
investigators were blinded. Two trials were rated as having low risk
of detection bias, as study authors stated that outcome assessors
were blinded (Chogtu 2016; Moosavi 2013). The five remaining
trials were rated as having unclear risk of detection bias, as none
provided details of blinding of outcome assessors (Balaguer 2016;
Criner 2014; Lee 2008; Lee 2009; Neukamm 2014).
Incomplete outcome data
Four studies were rated as having low risk of attrition bias, as
the rate of dropouts was low and similar between groups (Criner
2014; Lee 2008; Moosavi 2013; Neukamm 2014). Three of these
studies also used intention-to-treat analysis. Two studies were
rated as having unclear risk of attrition bias (Chogtu 2016; Mroz
2015). Chogtu 2016 reported few postrandomisation dropouts but
all occurred in the intervention group (6.25%). In Mroz 2015, only
one person dropped out following randomisation; however given
the small sample size, this represented 16.7% of the control group.
It is unclear whether an intention-to-treat analysis was used in
either of these trials. Two studies were rated as having high risk of
attrition bias, as postrandomisation dropout rates were high (25%
in each arm in Balaguer 2016, and 15.6% in the intervention arm
and 21.2% in the placebo arm in Lee 2009). Study authors did not
state whether an intention-to-treat analysis was performed.
Selective reporting
Six studies could be linked with their protocols. Two of these studies
fully reported their outcomes and were rated as having low risk of
reporting bias (Balaguer 2016; Criner 2014). One study reported its
primary and secondary endpoints as specified in the protocol but
did not provide any outcome data for its stated tertiary outcomes
and therefore was rated as having unclear risk of bias (Neukamm
2014). Three studies did not clearly report all outcomes specified
in the protocol and were also rated as having unclear risk of bias
(Chogtu 2016; Moosavi 2013; Mroz 2015). Two studies could not be
linked to their protocols (Lee 2008; Lee 2009). Neither showed clear
evidence of selective outcome reporting, and they were rated as
having unclear risk of bias.
We did not construct a funnel plot to assess reporting bias, as we
included fewer than 10 studies in the review.
Other potential sources of bias
All trials were rated as having low risk of other potential sources of
bias.
E:ects of interventions
See: Summary of findings for the main comparison Statins
compared to placebo as adjunct therapy for chronic obstructive
pulmonary disease (COPD)
Primary outcomes
Number of COPD exacerbations
Criner 2014 was the only study to report the number of
exacerbations in detail. The definition of exacerbations used
was "an increase in severity or new onset of two or more
respiratory symptoms (cough, sputum, wheezing, dyspnoea, or
chest tightness) lasting for at least three days and requiring
treatment with antibiotics or systemic glucocorticoids". Criner
2014 reported a total of 1982 acute COPD exacerbations in 877
participants (965 exacerbations among 430 in the intervention
group, and 1017 exacerbations among 447 in the control group).
There was no statistically significant diIerence between groups,
with 1.36 ± 1.61 exacerbations per person-year in the intervention
group and 1.39 ± 1.73 exacerbations per person-year in the control
group (P = 0.54; mean diIerence (MD) -0.03, 95% confidence interval
(CI) -0.25 to 0.19; Analysis 1.1). A total of 296 of 877 participants
(33.8%) had three or more exacerbations during the study (141
(32.8%) among 430 in the intervention group and 155 (34.7%)
among 447 in the control group; the diIerence was not significant).
There was no clear diIerence in the median number of days to the
first exacerbation (223 days (95% CI 195 to 275) in the intervention
group and 231 days (95% CI 193 to 303) in the control group; P =
0.34).
Criner 2014 also reported the number of exacerbations categorised
by severity: the number of exacerbations requiring hospitalisations
was 205 in the intervention group and 240 in the control group.
The mean number of exacerbations requiring hospitalisation per
person-year was 0.31 (95% CI 0.24 to 0.38) in the intervention group
and 0.31 (95% CI 0.23 to 0.38) in the control group (MD 0.00, 95%
CI -0.10 to 0.10; Analysis 1.2). Age, gender, smoking status, GOLD
stage, oxygen therapy, and location did not influence the mean
exacerbation rates.
Neukamm 2014 was the other study that reported numbers of
exacerbations. "Exacerbation" was defined according to current
GOLD guidelines as "having an acute event characterised by
worsening of the patient's respiratory symptoms that is beyond
normal day-to-day variation and leads to a change in medication".
Researchers reported the frequency of exacerbations during the
treatment period as 15% in the intervention group and 27% in the
placebo group, but this diIerence was not statistically significant
(P = 0.16). They reported exacerbations requiring hospitalisation
during the treatment period as 4 (9%) in the intervention group and
3 (6%) in the control group. It is unclear whether these numbers
represent events or people.
All-cause mortality
Statin treatment had no eIect on all-cause mortality, which
was reported in two trials (Criner 2014; Neukamm 2014). No
statistically significant diIerence was seen between groups (odds
ratio (OR) 1.03, 95% CI 0.61 to 1.74; I2 = 0%, P = 0.91; 2 trials,
952 participants; Analysis 1.3), with no heterogeneity. A wide
confidence interval suggests uncertainty about the precision of the
result. This evidence was downgraded to low quality given the
unclear risk of selection, detection, and reporting bias and the
imprecision of trial results.
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
COPD-specific mortality
COPD-specific mortality was described in one trial (Criner 2014),
which reported six deaths due to acute exacerbation in the
intervention group (1.4%) and five in the placebo group (1.1%) (OR
1.25, 95% CI 0.38 to 4.13, 1 trial, 877 participants; Analysis 1.4). This
result had a very wide confidence interval, which again suggests
uncertainty about the precision of the result.
Quality of life
Quality of life measures were reported in three studies, but we were
unable to pool the data, given the way they were reported. Both
Criner 2014 and Mroz 2015 used the SGRQ, and Chogtu 2016 used
the CCQ. Criner 2014 reported median change from baseline score
and found no significant improvement in any of the domains of
the SGRQ (total SGRQ median change from baseline -0.18 (10th,
90th percentiles -11.01, 9.7) in the intervention group and 0.02
(10th, 90th percentiles -12.47, 10.73) in the control group; P =
0.3783) nor on the Short Form Health Survey (SF-36), with statin
treatment. Mroz 2015 found that the median SGRQ score decreased
significantly (P = 0.012) from 54.5 to 42 in the intervention group
and noted no change in the control group (68 to 70 points; non-
significant) but did not provide a between-group analysis. Chogtu
2016 found that mean change in CCQ total score (P = 0.96) and
symptom score (P = 0.12) was not significant at 12 weeks but did
not provide further data.
Functional capacity
Six studies reported functional capacity. Lee 2008 and Lee 2009
reported the Naughton exercise stress test, and four trials reported
6MWD (Balaguer 2016; Moosavi 2013; Mroz 2015; Neukamm 2014).
Neukamm 2014 simply stated that there was no diIerence in
the 6MWD between the two groups but provided no data. The
remaining three trials were included in the meta-analysis, which
showed no statistically significant diIerence between the two
groups (MD 1.79, 95% CI -52.51 to 56.09; I2 = 0%, P = 0.95; 3
trials, 71 participants). This result has wide confidence intervals,
which exceed the minimum clinically important distance for the
6MWD, suggesting uncertainty about the precision of the result.
This analysis includes unpublished data from Mroz 2015. A baseline
imbalance between the two groups was evident in Mroz 2015, with
baseline 6MWD of 404 m (standard deviation (SD) 138.31 m) in
the control group and 367 m (SD 81.69) in the intervention group.
A sensitivity analysis excluding Mroz 2015 showed similar results
(MD 5.33, 95% CI -54.34 to 64.99; I2 = 0%, P = 0.86; 2 trials, 54
participants).
Lung function including spirometric measurement
Five studies reported FEV1 (% predicted) in a way that
could be included in the meta-analysis. ALer corresponding
with study authors, we included unpublished data from Mroz
2015. No statistically significant diIerence was evident between
intervention and control groups (MD 1.18, 95% CI -2.6- to 4.97; I2
= 0%, P = 0.54; 6 trials, 325 participants; Analysis 1.6). A sensitivity
analysis excluding Mroz 2015 showed similar results (MD 0.52, 95%
CI -3.36 to 4.40; I2 = 0%, P=0.54; 5 trials, 308 participants). The
same six studies also reported FEV1/FVC (%) in a way that could
be included in the meta-analysis. Results showed slightly higher
FEV1/FVC in the intervention group than in the placebo group (MD
2.66, 95% CI 0.12 to 5.2; I2 = 0%, P = 0.04; 6 trials, 325 participants;
Analysis 1.7). A sensitivity analysis excluding Lee 2009, which was
at high risk of attrition bias, and Mroz 2015, which was at high
risk of performance and detection bias, showed no statistically
significant diIerence between groups for either FEV1 (% predicted)
(MD -0.06, 95% CI -4.35 to 4.22; I2 = 0%, P = 0.98; 4 trials, 255
participants) or FEV1/FVC (%) (MD 2.05, 95% CI -0.87 to -4.97; I2 =
0%, P = 0.17; 4 trials, 255 participants). Again, Mroz 2015 showed
a baseline imbalance between the two groups, with baseline FEV1
(% predicted) of 50.4 (SD 11.55) in the control group and 59.58 (SD
20.43) in the intervention group.
Airway inflammation
Five trials reported measures of airway inflammation. Balaguer
2016 reported post-treatment IL-6 and IL-8 as mean and standard
deviations. Lee 2008 reported post-treatment CRP and IL-6 as
mean values with standard deviations. Mroz 2015 reported post-
treatment CRP in graph form as median values with 25th and 75th
percentiles. Neukamm 2014 reported post-treatment CRP and IL-6
as median values with 25th and 75th percentiles. They found a
significant reduction in high-sensitivity CRP level (20% vs 11%; P
= 0.017) and a significant attenuation of the rise in the level of
IL-6 (8% vs 30%; P = 0.028) in the intervention group compared
with the control group. Moosavi 2013 stated that "no significant
diIerence in the CRP was found between the two groups at baseline
or 6 months" but did not provide any figures. In correspondence
with study authors, Mroz 2015 provided mean + SD for CRP and
Moosavi 2013 provided figures for positive and negative CRP. Three
studies were included in the meta-analysis of CRP, which showed
a significant slight reduction in CRP in the intervention group (MD
-1.03, 95% CI -1.95 to -0.11; I2 = 0%, P = 0.03; 3 trials, 142 participants;
Analysis 1.8) (Balaguer 2016; Lee 2008; Mroz 2015). Again there was
a baseline imbalance between the two groups in Mroz 2015, with
baseline CRP (mg/L) of 4.76 (SD 7.99) in the control group and 9.33
(SD 6.32) in the intervention group. A sensitivity analysis excluding
Mroz 2015 showed similar results (MD -1.05, 95% CI -1.98 to -0.12;
I2 = 31%, P = 0.03; 2 trials, 125 participants). Two studies were
included in the meta-analysis of IL-6, which showed a significant
reduction in IL-6 in the intervention group (MD -2.11, 95% CI -2.65
to -1.56; I2 = 0%, P ≤ 0.00001; 2 trials, 125 participants; Analysis 1.9)
(Balaguer 2016; Lee 2008).
Adverse events
Criner 2014 reported rates of serious non-fatal adverse events and
indicated that rates of all non-fatal adverse events (the number of
serious adverse events per person-year) were similar in both groups
(0.63 ± 1.56 events (intervention group) and 0.62 ± 1.48 events
(control group)). This finding was not statistically significant, with
P > 0.20 for all comparisons, except for non-fatal serious adverse
events involving the gastrointestinal tract, which were significantly
more frequent in the intervention groups (in 30 patients (0.05
events per person-year) vs 17 patients (0.02 events per person-
year); P = 0.02). Neukamm 2014 lists the total numbers and
percentages of adverse events (12 (26%) in the intervention group
and 21 (43%) in the control group) and serious adverse events (4
(9%) in the intervention group and 3 (6%) in the control group).
Study authors state that there were no suspected unexpected
serious adverse reactions in either group. Balaguer 2016 states
that "no participants reported adverse eIects from simvastatin
treatment"; however study authors also state that "one patient
in intervention group not included in final analysis had a severe
exacerbation of COPD requiring ICU admission, one patient in the
intervention group had a severe adverse event and wasn't included
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in the final analysis, one patient in control group not included in
final analysis died from CAP". Chogtu 2016 stated that "rosuvastatin
was well tolerated by patients. Common adverse drug reactions
were gastric intolerance, myalgia, and elevated AST. The increase in
blood sugar was seen in three patients in rosuvastatin group and
two in placebo group. Pedal edema was seen in two patients in the
placebo group who were on calcium channel blockers. Seventeen
per cent of patients in rosuvastatin group had elevated AST at
three months, which reversed aLer one month of stopping drug.
Two patients had elevated CPK at three months, with associated
muscle pain, which was < three times upper limit of normal (ULN)
and reversed on stoppage of medicine". Lee 2008 and Lee 2009
stated that "pravastatin was very well-tolerated by all patients,
and none had any significant subjective side eIects". Moosavi 2013
stated that "atorvastatin was very well-tolerated by all patients,
and none of them had any significant subjective side eIects, such
as abnormal levels of liver and muscle enzymes". Mroz 2015 stated
that "no side eIects of the treatment were reported during the
study period".
D I S C U S S I O N
Summary of main results
Eight studies including 1323 participants with chronic obstructive
pulmonary disease (COPD) were included in the review.
Participants had a mean age of 61.4 to 72 years, and most were
male (median 73.4%). Mean baseline forced expiratory volume
in one second (FEV1) ranged from 41.5% to 59.6% predicted.
All studies compared moderate- or high-intensity statin therapy
versus placebo (Stone 2014). The duration of the intervention
ranged from 12 weeks to 36 months. Statin treatment did not
improve the number or severity of exacerbations, mortality, lung
function, functional capacity, or quality of life. It was associated
with a small reduction in C-reactive protein (CRP) and interleukin-6
(IL-6). Many findings, including our primary outcomes of all-
cause and COPD-specific mortality, had wide confidence intervals,
suggesting uncertainty about the precision of the results. Statins
were generally well tolerated with no increased incidence of
adverse events in the intervention groups other than an increase in
non-fatal serious adverse events involving the GI tract in one trial.
Overall completeness and applicability of evidence
Most participants included in this review (877/1323) came from
one large randomised controlled trial (RCT) (Criner 2014). This
RCT (mean follow-up 641 ± 354 days in the intervention group,
639 ± 351 days in the control group) was also much longer in
duration than the other trials, in which follow-up ranged from 12
weeks to six months. This trial looked at a highly selected group of
participants with COPD. Three trials - Balaguer 2016; Criner 2014;
Neukamm 2014 - including the two trials that looked at the primary
outcomes of number of exacerbations and COPD-specific mortality
excluded participants with a history of hypercholesterolaemia or
cardiovascular disease (Criner 2014; Neukamm 2014). This is not
representative of the majority of the population with COPD, who
have multiple comorbidities, particularly cardiovascular disease.
In fact, it is diIicult for investigators to find potential participants
for these trials, given the high incidence of cardiovascular disease
and cardiovascular disease risk factors in people with COPD (Chen
2015). Also, most participants had moderate to severe COPD,
making the results less applicable to those with mild COPD. Trials
were conducted across many diIerent continents, which does
make the results more applicable to the international population.
Certainty of the evidence
We GRADED the primary outcomes as having moderate- or low-
certainty evidence (Summary of findings for the main comparison).
Reasons for downgrading of evidence were risk of bias and
imprecision. We noted unclear risk of detection and selection
bias in the trial that reported the number of exacerbations and
COPD-specific mortality. We detected unclear risk of selection,
detection, and reporting bias in trials reporting all-cause mortality.
Researchers reported a small number of events with wide
confidence intervals in both COPD-specific and all-cause mortality.
Follow-up in these trials ranged from 12 weeks to 36 months,
and we noted a vast diIerence in sample size among trials, with
the number of participants ranging from 18 to 885. Four of our
outcomes - number of exacerbations, COPD-specific mortality,
quality of life, and adverse events - were not included in the meta-
analysis, as they were reported in a usable way by only one trial.
One study included in the meta-analysis was single-blind and was
at high risk of performance and detection bias. Two trials were at
high risk of attrition bias. When sensitivity analyses were performed
while removing trials at high risk of bias, this did not change the
conclusions of the review.
Two studies that were identified as suitable for inclusion in the
review had to be excluded due to lack of available data, as no results
were available, although trials were completed six and seven years
ago. This raises concerns of possible publication bias.
Potential biases in the review process
We performed a thorough search for all relevant published
and unpublished data by searching clinical trial registries and
checking reference lists, in addition to searching several electronic
databases. Given the small number of studies included in the
review, we were unable to create a funnel plot to assess publication
bias. We contacted the authors of Lee 2008 and Lee 2009 before
including these in the review, as they had a number of similarities,
and we were concerned that they might be multiple reports of
the same study. Study authors confirmed that these were diIerent
studies with diIerent participants. We contacted the investigators
of all included studies to obtain further information on study
characteristics and outcomes. We received data from only two of
the investigators (Moosavi 2013; Mroz 2015). We also contacted the
authors of the two studies that we excluded due to lack of available
data but received no reply. Given the high rate of reporting bias,
unavailable data from these eight studies could potentially change
the outcome of the review if this information should be included
in future reviews. We could not perform all planned subgroup and
sensitivity analyses, given the small number of included studies.
Agreements and disagreements with other studies or
reviews
We found one systematic review and meta-analysis of RCTs looking
at the eIects of statins for COPD (Zhang 2017). The Zhang review
included three more trials than this Cochrane Review because
it included trials with a duration of intervention less than 12
weeks. Both reviews show no diIerence in all-cause mortality. The
Zhang review showed improvement in quality of life, six-minute
walk distance, and FEV1/forced vital capacity (FVC). Those review
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authors did not see a diIerence in CRP, whereas our review showed
a statistically significant reduction in both CRP and IL-6. DiIerences
in findings between the two reviews may be explained by their
inclusion of three trials with a very short duration of intervention
(four to eight weeks). Researchers also found no benefit among
participants from studies that excluded people with existing or
potential cardiovascular disease.
A meta-analysis that included both cohort studies and RCTs showed
that statins were associated with a significant reduction in the risk
ratio (RR) of all-cause mortality (RR 0.72, 95% confidence interval
(CI) 0.63 to 0.84; P < 0.01), with considerable heterogeneity (I2
= 86.8%) (Lu 2019). This meta-analysis did not include either of
the RCTs included in our review and reported all-cause mortality.
Review authors showed a reduction in the risk ratio of COPD-
specific mortality and acute exacerbations of COPD but did not
provide any data on the significance of these results. They also
showed improvement in lung function and in six-minute walk
distance and a reduction in CRP and IL-6. Review authors did
not comment on the quality of the studies included in the meta-
analysis. Another systematic review, which included one RCT (Lee
2008), along with observational studies, found that statins may
reduce morbidity in COPD (Dobler 2009).
Several systematic reviews and meta-analyses of observational
studies showed an association between statin use and decreased
mortality and exacerbations in people with COPD. Li 2017
showed a significant reduction in the hazard ratio (HR) of all-
cause mortality (HR 0.65, 95% CI 0.57 to 0.74; P < 0.01), with
substantial heterogeneity (I2 = 64%). There was no significant
reduction in COPD-specific mortality. Review authors also showed
a significantly reduced risk of exacerbations (HR 0.58, 95% CI 0.48 to
0.72; P < 0.01), with considerable heterogeneity (I2 = 83%), including
exacerbations requiring hospitalisation (HR 0.75, 95% CI 0.67 to
0.83; P = 0.03), with substantial heterogeneity (I2 = 64%). Subgroup
analyses for all-cause mortality show that eIect size was reduced
in the prospective studies and in the higher-quality studies. Review
authors did not adjust for confounders in their analysis, and some
of the included studies did not control for confounders. Cao 2015
showed that statins significantly reduced all-cause mortality (HR
0.62, 95% CI 0.52 to 0.73; P = 0.001), with substantial heterogeneity
(I2 = 70.1%). There was no significant reduction in COPD-specific
mortality. Review authors also showed a significantly reduced risk
of exacerbations (HR 0.64, 95% CI 0.55 to 0.75; P = 0.011), with
substantial heterogeneity (I2 = 66.1%). Horita 2014 found that
statins may significantly reduce all-cause mortality (HR 0.81, 95%
CI 0.75 to 0.86; P < 0.001), with moderate heterogeneity (I2 = 52%).
Our review goes against these results, as we have not demonstrated
that statins result in a diIerence in morbidity or mortality among
people with COPD. A large cohort study indicates that statin use
may be associated with reduced risk of exacerbations of COPD only
in patients with coexisting cardiovascular disease (Ingebrigtsen
2015). This cohort of patients was not included in the majority of
trials that analysed our outcomes; this may be why disagreement is
apparent between the findings of this review and of observational
studies done in a more general population with COPD. The high
level of heterogeneity in these reviews reflects the variation in
included studies. Most of the trials in our review were short (six
months or less in duration) and therefore were not designed to
demonstrate the long-term benefits of statins, unlike observational
studies, which tend to follow participants for longer periods.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review did not show any clear clinical benefit or harm in
prescribing statins for patients with COPD for whom statins were
not otherwise indicated, but many results were uncertain. We did
see a significant reduction in CRP and IL-6 among patients who
received statins, but this did not translate into improved clinical
outcomes.
Implications for research
Further long-term RCTs on this topic are needed - ideally
studies that include participants who are more representative
of the real-world cohort of COPD patients, many of whom have
multiple comorbidities including cardiovascular disease. Given the
established role of statins in the management of people with
cardiovascular disease, it is unlikely there will ever be the clinical
equipoise to undertake such an RCT in this cohort of people. Future
studies would need to be powered to detect whether patients
in whom statins reduce inflammatory markers are less likely to
suIer exacerbations and hospitalisations. We included trials of 12
weeks or longer, as we believe this is the minimum time necessary
to ascertain whether statins had any eIect on outcomes among
people with COPD. Future trials should be at least six months in
duration to assess whether a reduction in inflammatory markers is
associated with a clinical eIect (EMA 2012).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Aim: to further explore the pleiotropic effects of statins in COPD, we designed a randomised pilot clin-
ical trial to investigate comprehensively their potential effects on (1) lung function, (2) systemic and
pulmonary inflammation, (3) endothelial function and growth factors involved in vascular homeostasis
(erythropoietin (Epo) and vascular endothelial growth factor (VEGF)), and (4) serum uric acid (UA)
Design: pilot, double-blind, randomised, placebo-controlled clinical trial
Duration: 12 weeks
Location: Spain
Participants Population: 24 participants were randomly assigned to receive simvastatin 40 mg daily (12) and place-
bo (12). 18 were included in the primary analysis (9 simvastatin and 9 placebo)
Baseline characteristics:
Mean age (years): simvastatin 69.3, placebo 66.4
% male: simvastatin 88.9, placebo 77.8
% FEV1 predicted: simvastatin 53.4, placebo 48.2 (post bronchodilator)
% baseline severity of COPD: simvastatin: GOLD A 44.4, GOLD B 11.1, GOLD C 33.3, GOLD D 11.1; place-
bo: GOLD A 33.3, GOLD B 11.1, GOLD C 33.3, GOLD D 22.2
% current smokers: none
Inclusion criteria: former smokers with stable COPD and moderate to severe airflow limitation
Exclusion criteria: hospitalisation or treatment changes within the previous 12 weeks, other concomi-
tant chronic inflammatory disease, history of active coronary artery disease, cerebrovascular or periph-
eral vascular disease, a fasting level of total cholesterol > 220 mg/dL, had received statin therapy be-
fore
Interventions Simvastatin 40 mg orally once daily
Comparison: placebo
Concomitant medications:
LA-b2: simvastatin 8 (88.9%), placebo 7 (77.8%)
LA anticholinergic: simvastatin 7 (77.8%), placebo 6 (66.7%)
Inhaled corticosteroids: simvastatin 6 (66.7%), placebo 7 (77.8%)
SA-b2: simvastatin 4 (44.4%), placebo 2 (22.2%)
SA anticholinergic: simvastatin 1 (11.1%), placebo 2 (22.2%)
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ASA: simvastatin 2 (22.2%), placebo 2 (22.2%)
ACEI: simvastatin 2 (22.2%), placebo 3 (33.3%)
ARBs: simvastatin 2 (22.2%), placebo 2 (22.2%)
Diuretics: simvastatin 2 (22.2%), placebo 2 (22.2%)
Outcomes Lung function: FEV1, FVC, DLCO, 6MWD
Systemic and pulmonary inflammation: sputum and blood IL-6 and IL-8, blood leukocytes, neu-
trophils, CRP, uric acid
Adverse events
Others: endothelial function (vascular stiffness), circulating vascular growth factors
Notes Funding: this study was funded by SEPAR 2006. All funds were used to carry out all laboratory analyses
and ELISAs
Possible conflicts of interest: study authors declare that they have no competing interests
Study number: NCT02070133
Definitions: COPD was defined using GOLD criteria
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information given on random sequence generation
Allocation concealment
(selection bias)





Low risk Double-blinded study
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Low risk All stated outcomes reported




Methods Aim: to evaluate the effects of rosuvastatin on pulmonary function and echocardiogram in patients
with COPD and related secondary PH as compared to placebo; to evaluate the effects of rosuvastatin
on exercise capacity and quality of life in COPD patients
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Design: interventional, randomised, prospective, double-blind, placebo-controlled, parallel study
Duration: 12 weeks
Location: India
Participants Population: 62 patients were randomised into rosuvastatin (32) and placebo (30) groups. 60 were in-
cluded in the primary analysis (30 rosuvastatin and 30 placebo)
Baseline characteristics:
Mean age (years): rosuvastatin 61.4, placebo 65.9
% male: not stated
% FEV1 predicted: not stated
% baseline severity of COPD: not stated
% current smokers: not stated
Inclusion criteria: patients of either gender between 40 and 80 years of age; patients with diagnosis of
COPD as per ATS standards and GOLD guidelines, with routine echocardiography showing mild to se-
vere PAH (30 mmHg < systolic pulmonary artery pressure (sPAP) > 75 mmHg); patients who were stable
for at least 2 weeks
Exclusion criteria: patients with asthma, periodic wheezing, bronchiectasis, pneumothorax, pleural
effusion, or pulmonary embolism liner disorder; patients with cardiac disorders such as arrhythmias
or unstable angina pectoris; patients on lipid-lowering agents; patients unable to perform 6MWT; preg-
nant/lactating women
Interventions Rosuvastatin 10 mg orally once daily
Comparison: placebo
Concomitant medications: not stated
Outcomes Lung function: FEV1, FVC, PEFR
Fuctional capacity: 6-minute walk test




Possible conflicts of interest: no conflicts of interest
Study number: CTRI/2012/12/003223
Definitions: COPD was defined using ATS and GOLD criteria
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was carried out using a pre-established computer-based se-
quence
Chogtu 2016  (Continued)
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Allocation concealment
(selection bias)
Low risk Randomisation was carried out using a pre-established computer-based se-





Low risk The randomised code number was noted in the clinical file of each patient
and in a separate register to identify the patient. Rug kits were labelled with a
patient-specific randomisation code to blind the investigator. Patients were
maintained on treatment in a double-blind fashion for 3 months, and the
treatment code was opened when the last patient completed his follow-up pe-
riod
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Investigators who carried out the endpoint assessments - QOL questionnaire




Unclear risk Low number of postrandomisation dropouts, but all occurred in the interven-
tion group (6.25%). Unclear whether intention-to-treat analysis was used
Selective reporting (re-
porting bias)
Unclear risk Reported outcomes stated in protocol; outcomes incompletely reported; sub-
group analysis reported for one outcome only




Methods Aim: to examine the effects of daily treatment with simvastatin for at least 12 months (range 12 to 36)
on the rate of exacerbation among patients with moderate to severe COPD and no other indications for
statin treatment
Design: randomised, double-blind, parallel-group, placebo-controlled multi-centre trial
Duration: 12 to 36 months
Location: 45 centres in Canada and the USA
Participants Population: 885 participants were randomly assigned to receive simvastatin 40 mg daily (N = 433) and
placebo (N = 453). 877 were included in the primary analysis (430 simvastatin and 447 placebo)
Baseline characteristics:
Mean age (years): simvastatin 62.2, placebo 62.3
% male: simvastatin 57.5, placebo 55.1
% FEV1 predicted: simvastatin 41.5, placebo 41.6 (post bronchodilator)
% baseline severity of COPD: simvastatin: GOLD 2 - 33, GOLD 3 - 32.3, GOLD 4 - 33; placebo: GOLD 2 -
36.3, GOLD 3 - 34, GOLD 4 - 31.4
% current smokers: simvastatin 30.7, placebo 31.6
Inclusion criteria: 40 to 80 years of age, at least moderate COPD, smoking history of 10 or more pack-
years, using supplemental O2 or having a history of receiving a course of systemic corticosteroids for
respiratory, visiting an emergency department or being hospitalised for a COPD exacerbation within
the past year, free of coronary artery or peripheral vascular disease
Exclusion criteria: patients who are on statins or should be on statins based on established risk strati-
fication; asthma; acute exacerbation in the previous 4 weeks; bronchiectasis; participants using niacin,
azole antifungals, fibric acid derivatives, erythromycin, clarithromycin, telithromycin, diltiazem, am-
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lodipine, ranolazine, HIV protease inhibitors, amiodarone, gemfibrozil, cyclosporine, verapamil, dana-
zol, nefazodone, and red yeast rice extracts; active liver disease; alcoholism; hypersensitivity to statins.
Subsequently, patients with diabetes and those on amlodipine or high-dose verapamil were withdrawn
from the study
Interventions Simvastatin 40 mg orally once daily
Comparison: placebo
Concomitant medications: patients were on ICS, LAMA, and LABA in various combinations
Outcomes COPD exacerbations: exacerbation rate, time to first exacerbation, exacerbation severity
All-cause mortality
COPD-specific mortality
Lung function: FEV1, FVC
Quality of life: SGRQ, SF-36
Adverse events: non-fatal serious adverse events, fatalities
Others: lipid levels, number of acute cardiovascular events
Notes Funding: NHLBI and Canadian Institutes of Health Research
Possible conflicts of interest: Dr. Bailey reports being a consultant to DLA Piper Law Firm re: Chantix
risks and benefits. Multiple study authors receive grant support and personal fees from pharmaceutical
companies outside the submitted work
Study number: NCT01061671
Definitions: COPD was defined using GOLD 2007 criteria; an exacerbation was defined as an increase
in severity or new onset of 2 or more respiratory symptoms (cough, sputum, wheezing, dyspnoea, or
chest tightness) lasting at least 3 days and requiring treatment with antibiotics or systemic glucocorti-
coids
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Double-blind study - placebo medication identical to simvastatin in taste,
smell, consistency, and appearance
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Postrandomisation dropouts similar and below 20% in each group (simvas-
tatin 19 (4.4%); placebo 25 (5.5%)). Intention-to-treat analysis performed
Criner 2014  (Continued)
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Selective reporting (re-
porting bias)
Low risk All outcomes stated in the protocol are reported in the trial




Methods Aim: to determine whether pravastatin administration is effective in improving exercise capacity in pa-
tients with COPD, and whether baseline or serial changes in hs-CRP over time are associated with cor-
responding changes in exercise capacity
Design: randomised, placebo-controlled, double-blind, parallel-group clinical trial
Duration: 6 months (plus run-in period of 2 weeks)
Location: Taiwan
Participants Population: 125 participants were randomly assigned to pravastatin (62) or placebo (63). 107 partici-
pants completed the study (53 pravastatin and 54 placebo)
Basline characteristics:
Mean age (years): pravastatin 70 (± 8), placebo 71 (± 6)
% male: pravastatin 79, placebo 73
% current smokers: pravastatin 81, placebo 76
% FEV1 predicted: pravastatin 51, placebo 56
Inclusion criteria: stable COPD (ATS criteria) for > 3 months, 40 to 80 years of age
Exclusion criteria: acute exacerbations of COPD, any active infection, renal disease (serum creatinine
concentration 1.5 mg/dL or 133 mol/L) for 3 months before entry into the study. To exclude patients
with asthma, people with 1 of the following features were excluded from the study: history of perennial
allergic rhinitis, periodic wheezing, pulmonary embolism, improvement in FEV1 of 15% from predicted
values after inhalation of a bronchodilator; before they were enrolled in this study, no patients had ever
received cholesterol-lowering agents
Interventions Pravastatin 40 mg orally once daily for 6 months
Comparison: placebo
Concomitant medications:
All medications for COPD were kept constant throughout the study. Other concomitant medications
considered necessary for each patient's well-being could be given at the investigator's discretion
Steroid dependent: pravastatin 30 (48%), placebo 33 (52%)
Theophylline: pravastatin 53 (86%), placebo 54 (86%)
Outcomes Lung function: FEV1, FVC
Functional capacity: Naughton exercise stress test, Borg dyspnoea scale
Airway inflammation: CRP, IL-6
Adverse events: no significant subjective side effects
Others: serum lipids
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Notes Funding: grants CMFHT9501, CMFHR9502, CMFHR9503, and CM-TMU9601 from the Chi-Mei Medical
Center, Tainan, Taiwan; grant NSC 95-2314-B-384-009 from the National Science Council, Taiwan, Re-
public of China. Pravastatin was in part a generous giL from Sankyo Company, Ltd., Tokyo, Japan
Possible conflicts of interest: not stated
Study number: PMID: 18312772
Definitions: COPD was defined using ATS criteria (FEV1 < 80% predicted values and FEV1/FVC ratio <
70%)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Each patient received a randomised code number, according to which the
study assistant supplied the study drug
Allocation concealment
(selection bias)
Low risk Special drug packaging was used to maintain blindness of treatment; a sealed
envelope, with information on treatment allocation, was kept in the clinical





Low risk Double-blind, placebo-controlled study
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Postrandomisation dropouts were similar and below 20% in both groups
(pravastatin 9 (14.5%), placebo 9 (14.3%))
Selective reporting (re-
porting bias)
Unclear risk Trial protocol against which to check all prespecified outcomes could not be
located; all outcomes stated in the report were reported




Methods Design: randomised, double-blind, parallel-group, placebo-controlled, single-centre trial
Duration: 6 months (plus 2-week run-in period)
Location: Taiwan
Participants Population: 65 participants were randomly assigned to pravastatin (32) or placebo (33). 53 partici-
pants completed the study (27 pravastatin and 26 placebo)
Baseline characteristics:
Mean age (years): pravastatin 71, placebo 72
% male: pravastatin 74.1, placebo 73.1
% FEV1: pravastatin 55.9, placebo 57.4
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% current smokers: pravastatin 81, placebo 81
Inclusion criteria: COPD (ATS criteria); stable for at least 3 months; 40 to 80 years of age; routine echo
showed pulmonary hypertension
Exclusion criteria: acute exacerbations of COPD, any active infection, or renal disease (serum crea-
tinine concentration 1.5 mg/dL or 133 μmol/L) for at least 3 months before entry into the study; asth-
ma; periodic wheezing; pulmonary embolism; history of perennial allergic rhinitis; improvement in
FEV1 > 15% from predicted values after inhalation of a bronchodilator. No patients had received choles-
terol-lowering agents before they were enrolled in the study
Interventions Pravastatin 40 mg orally once daily for 6 months
Comparison: placebo
Concomitant medications: all medication for COPD was kept constant throughout the study. Other
concomitant medication considered necessary for the well-being of each patient could be given at the
investigator's discretion
Steroid dependent: pravastatin 16 (59%), placebo 14 (54%)
Theophylline: pravastatin 25 (93%), placebo 26 (96%)
Beta2-adrenoreceptor agonist: pravastatin 20 (74%), placebo 21 (81%)
Anticholinergics: pravastatin 10 (37%), placebo 8 (31%)
Nocturnal oxygen supplementation: pravastatin 1 (4%), placebo 1 (4%)
Outcomes Lung function: FEV1, FVC, TLC, IC
Functional capacity: Naughton exercise stress test, Borg dyspnoea scale
Airway inflammation: plasma and urinary ET-1
Adverse events: no significant subjective side effects
Others: changes in cardiac index and systolic pulmonary artery pressure measured on echocardiogram
Notes Funding: Chi-Mei Medical Center (grant numbers CMFHT9501, CMFHR9702, 97CM-TMU01); Department
of Health, Taiwan, Republic of China (DOH97-TD-I-111-TM001). Pravastatin was, in part, a generous giL
from Sankyo Co. Ltd. (Tokyo, Japan)
Possible conflicts of interest: none stated
Study number: PMID: 18831711
Definitions: COPD was defined by ATS criteria (FEV1 < 80% of predicted values and FEV1/FVC ratio <
70%)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Each patient received a randomised code number, according to which the
study assistant supplied the study drug
Allocation concealment
(selection bias)
Low risk Special drug packaging was used to maintain blindness to treatment; a sealed
envelope, with information on the treatment allocated, was kept in the clinical
file of each patient
Lee 2009  (Continued)
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Low risk Double-blind, placebo-controlled study
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Postrandomisation dropouts were slightly higher and above 20% in the place-
bo group (pravastatin 5 (15.6%), placebo 7 (21.2%)). It is not stated whether an
intention-to-treat analysis was performed
Selective reporting (re-
porting bias)
Unclear risk Trial protocol against which to check all prespecified outcomes could not be
located. Most outcomes measured were surrogate outcomes




Methods Aim: to investigate the effects of atorvastatin on reducing pulmonary hypertension of patients with
COPD
Design: randomised, triple-blind, parallel-group, controlled trial
Duration: 6 months
Location: Iran
Participants Population: 45 patients were randomly assigned to atorvastatin (24) or placebo (21). 36 patients com-
pleted the study (19 atorvastatin and 17 placebo)
Baseline characteristics:
Mean age (years): atorvastatin 65, placebo 68
% male: atorvastatin 62.5, placebo 61.9
% FEV1: atorvastatin 44, placebo 43.5
Inclusion criteria: systolic pulmonary hypertension > 40 mmHg; no history of prostanoids, statins, en-
dothelin antagonists, and phosphodiesterases; able to do 6MWT; obstructive pattern in PFTs and func-
tional class II, III (NYHA); over 18 years of age
Exclusion criteria: PAH with underlying cause other than COPD; LDL < 70 mg/dL; ALT or AST > 3x upper
limit of normal
Interventions Atorvastatin 20 mg orally twice daily for 6 months
Comparison: placebo
Concomitant medications: not specified
Outcomes All-cause mortality
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Adverse events: no significant subjective side effects
Others: systemic pulmonary arterial hypertension, cardiac output, right ventricular size, oxidised LDL
levels, patients' signs and symptoms
Notes Funding: Tehran University of Medical Sciences
Possible conflicts of interest: not stated
Study number: IRCT201108257411N1
Definitions: COPD was defined using ATS criteria
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Patients, research analyser, and outcome assessors (other than the data co-or-
dinating person) were blind until the study was completed
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Patients, research analyser, and outcome assessors (other than the data co-or-




Low risk Postrandomisation dropouts were similar and below 20% in both groups (ator-




Unclear risk Not all outcomes specified in the protocol were reported




Methods Aim: to determine whether statins have an anti-inflammatory effect on the lungs of COPD patients
Design: randomised, single-blind, placebo-controlled, parallel-group pilot study
Duration: 12 weeks (plus 4-week washout period)
Location: Poland
Participants Population: 18 patients randomly assigned to atorvastatin (12) or placebo (6). 17 patients completed
the study (12 atorvastatin and 5 placebo)
Baseline characteristics:
Mean age (years): atorvastatin 64.6, placebo 68.4
% male: atorvastatin 91.7, placebo 100
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% FEV1: atorvastatin 59.6, placebo 50.4
% current smokers: atorvastatin 41.7, placebo 40
Inclusion criteria: male and female adults aged ≥ 40 years who have signed an informed consent form
before initiation of any study-related procedure; patients with moderate to very severe stable COPD
(stage II to IV) according to GOLD guidelines; patients with postbronchodilator FEV1 < 80% of predict-
ed normal and a postbronchodilator FEV1/FVC < 0.70 at visit 1; current smokers or ex-smokers with a
smoking history of at least 10 pack-years
Exclusion criteria: pregnant or nursing (lactating) women; women of childbearing potential, unless
they are using effective methods of contraception during dosing of study treatment; patients with a
clinically significant abnormality at visit 1; patients with a clinically relevant laboratory abnormality at
visit 1; patients with a history of malignancy of any organ system (including lung cancer); patients con-
traindicated for treatment with statins; patients unable to perform acceptable spirometry and lung vol-
umes procedures; patients who have had a COPD exacerbation that required treatment with antibiotics
and/or OCS and/or hospitalisation in the 6 weeks before visit 1; patients who have had a respiratory
tract infection within 4 weeks before visit 1; patients requiring oxygen therapy (> 15 hours/d) on a dai-
ly basis for chronic hypoxaemia; patients with any history of asthma or onset of symptoms before age
40 years; patients with concomitant pulmonary disease (e.g. lung fibrosis, sarcoidosis, interstitial lung
disease, pulmonary hypertension, tuberculosis); patients with primary bronchiectasis; patients with a
diagnosis of α-1-antitrypsin deficiency; patients with pulmonary lobectomy or lung volume reduction
surgery or lung transplantation; patients participating in or planning to participate in the active phase
of a supervised pulmonary rehabilitation programme during the study; patients receiving certain med-
ications; patients using other investigational drugs within 30 days before visit 1
Interventions Atorvastatin 40 mg orally once daily for 12 weeks
Comparison: placebo
Concomitant medications: all patients received formoterol at a dose of 12 μg twice daily by easyhaler
and/or tiotropium bromide 18 μg once daily by handihaler as maintenance and salbutamol MDI 200 mg
as reliever treatment. Relief mediation with salbutamol MDI 200 μg as required was provided for addi-
tional symptom control as needed (but not within 6 hours before each visit). During 4 weeks of washout
period, ICSs were withdrawn
Outcomes Lung function: FEV1, IC, RV, TLC, DLCO
Functional capacity: 6MWD
Airway inflammation: CRP
Quality of life: SGRQ
Adverse events
Others: change in CD45+ cell expression measured by immunohistochemistry; changes in expression
of genes measured using microarrays in lung biopsy (TBB) samples; intimal medial thickness in com-
mon carotid artery; serum lipids
Notes Funding: study was supported by National Science Centre (NCN) Project No: N N402 593440
Possible conflicts of interest: none declared
Study number: NCT01748279
Definitions: definition of COPD was based on presence of clinical symptoms (chronic cough and/or ex-
ertional dyspnoea), exposure to cigarette smoke (> 10 pack-years smoking), and postbronchodilator
FEV1/FVC ratio < 0.7 (ATS criteria)
Risk of bias
Mroz 2015  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients were randomised (2:1) using sequentially numbered containers
Allocation concealment
(selection bias)





High risk This was a single-blind study; personnel were not blinded at any stage
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk There were no postrandomisation dropouts in the atorvastatin group and 1
(16.7%) in the placebo group
Selective reporting (re-
porting bias)
Unclear risk Not all outcomes specified in the protocol were clearly reported




Methods Design: randomised, double-blind, parallel-group, placebo-controlled, multi-centre trial
Duration: 12 weeks
Location: Norway
Participants Population: 99 participants randomly assigned to rosuvastatin (49) or placebo (50). 94 patients were
included in the final analysis (47 rosuvastatin and 47 placebo)
Baseline characteristics:
Mean age (years): rosuvastatin 66, placebo 63
% male: rosuvastatin 55, placebo 49
% FEV1: rosuvastatin 48.3, placebo 52.1
% current smokers: rosuvastatin 26, placebo 49
Inclusion criteria: stable COPD without exacerbation the last 3 weeks before inclusion; COPD stage I to
IV according to GOLD criteria; between 40 and 80 years of age
Exclusion criteria: other diagnosed lung disease except chronic asthmatic bronchitis and mild
bronchiectasis without or with few physical signs (diagnosed by high-resolution computed tomogra-
phy); history of or active coronary artery disease, cerebrovascular or peripheral vascular disease; his-
tory of or clinically significant congestive heart failure, valvular heart disease, clinically significant ar-
rhythmias, or conduction delays; uncontrolled arterial hypertension (defined as blood pressure above
180/110 mmHg with or without the use of antihypertensive medication); body mass index > 40 kg/m2;
history of diabetes mellitus or measured fasting glucose > 11 mmol/L; history of hypercholesterolaemia
or measured total cholesterol > 8 mmol/L; known poliomyelitis, motor neuron disease, cranial or tem-
poral arteritis, stroke, or myopathy; neutropenia or anaemia (Hb < 8 g/dL); history of chronic renal fail-
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ure, serum creatinine > 176 mol/L (2.0 mg/dL), or creatine kinase > 3 times the upper limit of normal
(ULN); acute or chronic liver disease (serum transaminases > 3 times the ULN); pregnancy (self-report-
ed) and blood test before inclusion; active abuse of drugs or alcohol or poor compliance anticipated;
statin use within the last 4 weeks before study start or previously; clear indication for statin use; prior
diagnosis of statin-induced myopathy or hypersensitivity reaction to another statin including rosuvas-
tatin; history of malignant disease of any kind within 5 years before inclusion; history of uncontrolled
hypothyroidism; participation in another pharmaceutical or medical device clinical trial study with-
in 4 weeks before inclusion; use of concomitant medications that are known to interact with rosuvas-
tatin, including warfarin and other coumarin (vitamin K antagonist) anticoagulants, cyclosporine, gem-
fibrozil, and antacid, before inclusion
Interventions Rosuvastatin 10 mg orally once daily for 12 weeks
Comparison: placebo identical in appearance
Concomitant medications:
Antihypertensive treatment: rosuvastatin 12 (26%), placebo 10 (21%)
ICS (including LABA): rosuvastatin 36 (77%), placebo 34 (72%)
LABA only: rosuvastatin 2 (4%), placebo 3 (6%)
LAMA: rosuvastatin 30 (64%), placebo 27(58%)
Anti-inflammatory treatment: rosuvastatin 2 (4%), placebo 0
Oestrogen: rosuvastatin 4 (9%), placebo 3 (6%)
Outcomes Exacerbations: frequency, exacerbations requiring hospital admission
Lung function: FEV1, FVC
Functional capacity: 6MWD, MMRC dyspnoea scale
Airway inflammation: CRP, IL-6
Adverse events: adverse events and serious adverse events
Others: change in endothelium-dependent vascular function measured using peripheral arterial
tonometry and expressed as the reactive hyperaemia index
Notes Funding: grants from the Norwegian Extra Foundation for Health and Rehabilitation and the Nor-
wegian Association of Heart and Lung Patients. Support from the Investigator-Sponsored Study
Programme of AstraZeneca. Medication was provided by AstraZeneca. The sponsors, including As-
traZeneca, played no role in study design; collection, analysis, and interpretation of the data; or writing
of or decision to submit the manuscript for publication
Possible conflicts of interest: TO received grants, personal fees, and non-financial support from Ab-
bott Laboratories; personal fees from Siemens Healthcare; grants, personal fees, and non-financial
support from AstraZeneca; and personal fees from Roche Diagnostics. AN has received a speaker fee
from AstraZeneca. All other study authors have no conflicts of interest to declare
Study number: NCT00929734
Definitions: COPD was defined by GOLD criteria. Exacerbation was defined according to current GOLD
guidelines as having an acute event characterised by worsening of the patient's respiratory symptoms
that is beyond normal day-to-day variation and leads to a change in medication
Risk of bias
Bias Authors' judgement Support for judgement
Neukamm 2014  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk A computer-generated list of random numbers was used for allocation of pa-




Low risk Patients and all staI involved in the trial were blinded to the allocation. A da-
ta and safety monitoring board was responsible for applying a randomisation





Low risk Double-blind, placebo-controlled study
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Postrandomisation dropouts were similar and below 20% in both groups (ro-




Unclear risk Primary and secondary endpoints as stated in the trial protocol were clearly
reported. Tertiary outcome results were not fully reported
Other bias Low risk None identified
Neukamm 2014  (Continued)
6MWD: six-minute walking distance; 6MWT: six-minute walk distance test; ACEI: angiotensin-converting enzyme inhibitor; ALT: alanine
aminotransferase; ARB: angiotensin-receptor blocker; ASA: aminosalicylic acid; AST: aspartate aminotransferase; ATS: American Thoracic
Society; CCQ: Clinical COPD Questionnaire; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; DLCO: diIusing capacity
of the lungs for carbon monoxide; ELISA: enzyme-linked immunosorbent assay; Epo: erythropoietin; ET-1: endothelin-1; FEV1: forced
expiratory volume in one second; FVC: forced vital capacity; GOLD: Global initiative for Chronic Obstructive Lung Disease; hs-CRP: high-
sensitivity C-reactive protein; IC: inspiratory capacity; ICS: inhaled corticosteroid; IL: interleukin; LA: long-acting; LABA: long-acting beta2
agonist; LAMA: long-acting muscarinic antagonist; LDL: low-density lipoprotein; MDI: metered-dose inhaler; MMRC: Modified Medical
Research Council; NHLBI: National Heart, Lung and Blood Institute; NYHA: New York Heart Association; OCS: oral corticosteroid; PAH:
pulmonary arterial hypertension; PEFR: peak expiratory flow rate; PFT: pulmonary function test; QOL: quality of life; RV: residual volume;
SA: short-acting; SF-36: Short Form Health Survey; SGRQ: St. George's Respiratory Questionnaire; sPAP: systolic pulmonary pressure; TBB:
transbronchial biopsy; TLC: total lung capacity; UA: uric acid; ULN: upper limit of normal; VEGF: vascular endothelial growth factor.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
ACTRN12611000165987 Not randomised, not placebo controlled
Arian 2018 Not placebo controlled
Arutyunov 2007 Not placebo controlled
Du 2018 Not placebo controlled
Eudract no 2009-017689-22 6 weeks' duration
Eudract number
2007-003916-74  
Unable to identify published results despite apparent completion of study. Study authors contact-
ed but no response received
John 2015 6 weeks' duration
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Study Reason for exclusion
Kaczmarek 2010 Not placebo controlled
Maneechotesuwan 2015 4 weeks' duration, cross-over trial
Mohammed 2012 4 weeks' duration
Morris 2017 COPD not defined by standard criteria
NCT00655993 9 weeks' duration, cross-over trial
NCT00680641 2 months' duration
NCT00700921 Unable to identify published results despite apparent completion of study. Study authors contact-
ed but no response received
Rizvi 2013 Quasi-experimental design, not placebo controlled
Rossi 2017 COPD not defined by standard criteria
Undas 2009 Not placebo controlled
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Statins versus placebo
Outcome or subgroup
title
No. of studies No. of partici-
pants
Statistical method Effect size
1 Number of exacerba-
tions
1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 Exacerbations requir-
ing hospitalisation
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 All-cause mortality 2 952 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.61, 1.74]
4 COPD-specific mortality 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Six-minute walk dis-
tance
3 71 Mean Difference (IV, Fixed, 95% CI) 1.79 [-52.51, 56.09]
6 FEV1 (% predicted) 6 325 Mean Difference (IV, Fixed, 95% CI) 1.18 [-2.60, 4.97]
7 FEV1/FVC (%) 6 325 Mean Difference (IV, Fixed, 95% CI) 2.66 [0.12, 5.20]
8 CRP (mg/L) 3 142 Mean Difference (IV, Fixed, 95% CI) -1.03 [-1.95, -0.11]
9 Il-6 (pg/mL) 2 125 Mean Difference (IV, Fixed, 95% CI) -2.11 [-2.65, -1.56]
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Analysis 1.1.   Comparison 1 Statins versus placebo, Outcome 1 Number of exacerbations.
Study or subgroup Favours statin Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Criner 2014 430 1.4 (1.6) 447 1.4 (1.7) -0.03[-0.25,0.19]
Favours statin 21-2 -1 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Statins versus placebo, Outcome 2 Exacerbations requiring hospitalisation.
Study or subgroup Experimental Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Criner 2014 430 0.3 (0.7) 447 0.3 (0.8) 0[-0.1,0.1]
Favours [statin] 0.40.2-0.4 -0.2 0 Favours [placebo]
 
 
Analysis 1.3.   Comparison 1 Statins versus placebo, Outcome 3 All-cause mortality.
Study or subgroup Statin Placebo Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Moosavi 2013 1/24 1/21 3.7% 0.87[0.05,14.82]
Criner 2014 28/430 30/477 96.3% 1.04[0.61,1.77]
   
Total (95% CI) 454 498 100% 1.03[0.61,1.74]
Total events: 29 (Statin), 31 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.9); I2=0%  
Test for overall effect: Z=0.12(P=0.91)  
Favours statin 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Statins versus placebo, Outcome 4 COPD-specific mortality.
Study or subgroup Statin Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Criner 2014 6/430 5/447 1.25[0.38,4.13]
Favours statin 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Statins versus placebo, Outcome 5 Six-minute walk distance.
Study or subgroup Statin Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Balaguer 2016 9 455.6 (69.6) 9 444.4 (106) 42.95% 11.2[-71.65,94.05]
Moosavi 2013 19 339 (155) 17 340 (106) 39.86% -1[-87,85]
Mroz 2015 12 384.8 (83.8) 5 400 (139.3) 17.19% -15.25[-146.23,115.73]
   
Total *** 40   31   100% 1.79[-52.51,56.09]
Heterogeneity: Tau2=0; Chi2=0.12, df=2(P=0.94); I2=0%  
Favours placebo 200100-200 -100 0 Favours statin
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Study or subgroup Statin Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=0.06(P=0.95)  
Favours placebo 200100-200 -100 0 Favours statin
 
 
Analysis 1.6.   Comparison 1 Statins versus placebo, Outcome 6 FEV1 (% predicted).
Study or subgroup Statin Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Balaguer 2016 9 53.1 (12.9) 9 48.1 (10.7) 11.95% 5[-5.95,15.95]
Lee 2008 53 55 (19) 54 55 (14) 35.72% 0[-6.33,6.33]
Lee 2009 27 60.5 (20.4) 26 57.3 (13) 17.02% 3.2[-5.97,12.37]
Moosavi 2013 19 47.6 (28.4) 17 48.6 (19.3) 5.79% -1[-16.72,14.72]
Mroz 2015 12 61.5 (21.3) 5 47.6 (13.7) 4.94% 13.9[-3.14,30.94]
Neukamm 2014 47 49.3 (18.9) 47 51.7 (18.9) 24.58% -2.4[-10.04,5.24]
   
Total *** 167   158   100% 1.18[-2.6,4.97]
Heterogeneity: Tau2=0; Chi2=3.85, df=5(P=0.57); I2=0%  
Test for overall effect: Z=0.61(P=0.54)  
Favours placebo 2010-20 -10 0 Favours statin
 
 
Analysis 1.7.   Comparison 1 Statins versus placebo, Outcome 7 FEV1/FVC (%).
Study or subgroup Statin Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Balaguer 2016 9 46.3 (11.5) 9 41.9 (8.2) 7.59% 4.4[-4.83,13.63]
Lee 2008 53 58 (14) 54 54 (7) 36.53% 4[-0.21,8.21]
Lee 2009 27 58.5 (13.1) 26 54.5 (8.5) 18.42% 4[-1.92,9.92]
Moosavi 2013 19 55.9 (15.5) 17 57.4 (15.3) 6.37% -1.5[-11.57,8.57]
Mroz 2015 12 54.1 (14.9) 5 47.8 (7) 5.98% 6.3[-4.1,16.7]
Neukamm 2014 47 47.3 (12.8) 47 47.9 (12.3) 25.11% -0.6[-5.67,4.47]
   
Total *** 167   158   100% 2.66[0.12,5.2]
Heterogeneity: Tau2=0; Chi2=3.44, df=5(P=0.63); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Favours placebo 2010-20 -10 0 Favours statin
 
 
Analysis 1.8.   Comparison 1 Statins versus placebo, Outcome 8 CRP (mg/L).
Study or subgroup Statin Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Balaguer 2016 9 5.1 (5.3) 9 3.8 (2.9) 5.47% 1.3[-2.65,5.25]
Lee 2008 53 2.7 (2.5) 54 3.9 (2.6) 93.03% -1.19[-2.15,-0.23]
Mroz 2015 12 5.7 (3.3) 5 5.2 (8.3) 1.5% 0.43[-7.11,7.97]
   
Total *** 74   68   100% -1.03[-1.95,-0.11]
Favours statin 105-10 -5 0 Favours placebo
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Study or subgroup Statin Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Heterogeneity: Tau2=0; Chi2=1.59, df=2(P=0.45); I2=0%  
Test for overall effect: Z=2.19(P=0.03)  
Favours statin 105-10 -5 0 Favours placebo
 
 
Analysis 1.9.   Comparison 1 Statins versus placebo, Outcome 9 Il-6 (pg/mL).
Study or subgroup Statin Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Balaguer 2016 9 5.6 (3.8) 9 7.4 (8.5) 0.81% -1.8[-7.88,4.28]
Lee 2008 53 3.7 (1) 54 5.8 (1.8) 99.19% -2.11[-2.66,-1.56]
   
Total *** 62   63   100% -2.11[-2.65,-1.56]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=7.56(P<0.0001)  
Favours statin 52.5-5 -2.5 0 Favours placebo
 
 
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)
Electronic searches: core databases
 
Database Dates searched Frequency of search
CENTRAL (via the Cochrane Register of Studies (CRS)) From inception Monthly
MEDLINE (Ovid) 1946 onwards Weekly
Embase (Ovid) 1974 onwards Weekly
PsycINFO (Ovid) 1967 onwards Monthly
CINAHL (EBSCO) 1937 onwards Monthly
AMED (EBSCO) From inception Monthly
 
 
Handsearches: core respiratory conference abstracts
 
Conference Years searched
American Academy of Allergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
 
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International Primary Care Respiratory Group Congress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
  (Continued)
 
MEDLINE search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.






Filter to identify RCTs
1. exp "clinical trial [publication type]"/









11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
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Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5









#16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 #6 AND #16
[In search line #4, MISC1 denotes the field in which the reference record has been coded for condition, in this case, COPD]
C O N T R I B U T I O N S   O F   A U T H O R S
• Conceiving the review - all authors.
• Designing the review - all authors.
• Co-ordinating the review - AW.
• Collecting data for the review - all authors.
• Designing search strategies - AW, MNC, LS.
• Undertaking searches - AW, LS.
• Screening search results - AW, LP.
• Organizing retrieval of papers - AW, LP.
• Screening retrieved papers against inclusion criteria - AW, LP.
• Appraising quality of papers - AW, LP.
• Extracting data from papers - AW, LP, MNC.
• Writing to authors of papers for additional information - AW.
• Providing additional data about papers - AW.
• Obtaining and screening data from unpublished studies - AW, MNC.
• Managing data for the review - AW.
• Entering data into RevMan - AW, MNC.
• Analysing data - AW, AK.
• Interpreting data - AW, AK.
• Providing a methodological perspective - AK.
• Providing a clinical perspective - MH.
• Writing the review - all authors.
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)









Cochrane Database of Systematic Reviews
Contributions of editorial team
Rebecca Fortescue (Co-ordinating Editor): edited the review; advised on methodology, interpretation, and content; and approved the final
review before publication.
Chris Cates (Co-ordinating Editor): checked data entry before the full write-up of the review.
Wouter H. van GeIen (Editor): edited the review; advised on methodology, interpretation, and content; and approved the final review
before publication.
Emma Dennett (Managing Editor): co-ordinated the editorial process; advised on interpretation and content; and edited the review.
Emma Jackson (Assistant Managing Editor): conducted peer review; and edited the plain language summary and reference sections of
the protocol and the review.
Elizabeth Stovold (Information Specialist): designed the search strategy; ran the searches; and edited the search methods section.
D E C L A R A T I O N S   O F   I N T E R E S T
MTH: my institution has received grant money from Novartis, and I have received payments for delivering lectures from GSK, Novartis,
Astra, Menarini, and Boehringer Ingelheim. I have never received any funds or support in the area of statins in COPD.
AK: none known.
MNC: has received honoraria from AstraZeneca for providing CME lectures to GPs. She has also attended respiratory meetings for CME, for
which accommodations, transport, and registration fees were paid by Novartis, Gilead, and Abbott.
LMP: none known.
AW: none known.
S O U R C E S   O F   S U P P O R T
Internal sources
• The authors declare that no internal sources of funding were received for this systematic review, Other.
External sources
• The authors declare that no external sources of funding were received for this systematic review, Other.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
One of the study authors (ME) was no longer able to participate in the review process.
Statins versus placebo for people with chronic obstructive pulmonary disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
43
